SCHEDULE 13D: Samsara BioCapital Discloses 61.2% Stake in Kalaris Therapeutics Following Merger

Samsara BioCapital, L.P., along with its general partner and managing member, has reported beneficial ownership of 61.2% of Kalaris Therapeutics, Inc. common stock following a recent merger.

Summary

• Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, and Dr. Srinivas Akkaraju (collectively, the "Reporting Persons") have filed a Schedule 13D, disclosing their beneficial ownership in Kalaris Therapeutics, Inc.
• The Reporting Persons collectively beneficially own 11,448,081 shares of Kalaris Therapeutics, Inc. common stock, representing 61.2% of the outstanding shares.
• This ownership stake was acquired in connection with the merger of Aurora Merger Sub, Inc. into Kalaris Tx, Inc. (formerly Legacy Kalaris) on March 18, 2025, where Legacy Kalaris became a wholly-owned subsidiary of the Issuer.
• At the effective time of the merger, each share of Legacy Kalaris common stock was converted into the right to receive 0.2016 shares of the Issuer's common stock.
• Samsara LP's shares of Legacy Kalaris stock were converted into an aggregate of 11,444,503 shares of the Issuer's common stock.
• The aggregate purchase price for the Legacy Kalaris securities acquired by Samsara LP was $60,007,111, funded by capital contributions from its partners.
• The Reporting Persons acquired these securities for investment purposes, aiming to increase the value of their investments and the Issuer.
• Dr. Srinivas Akkaraju, the Managing Member of Samsara GP, is a member of the Issuer's board of directors and may influence corporate activities.
• Certain executive officers, directors, and stockholders, including Samsara LP and Dr. Akkaraju, have entered into 180-day lock-up agreements, restricting the sale or transfer of their shares following the merger's closing date.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of a significant ownership stake following a merger. The large investment by a venture capital firm and board representation can be seen as a positive sign of commitment and strategic backing, though the document itself is neutral in tone.

Positives

• A significant ownership stake (61.2%) by a venture capital firm like Samsara BioCapital indicates strong investor confidence and a long-term commitment to Kalaris Therapeutics, Inc. post-merger.
• The presence of Dr. Srinivas Akkaraju, Managing Member of Samsara GP, on the Issuer's board of directors provides direct influence and strategic guidance from a major investor.
• The investment of over $60 million by Samsara LP into Legacy Kalaris (now part of Kalaris Therapeutics, Inc.) demonstrates substantial financial backing.

Risks

• The Reporting Persons reserve the right to dispose of all or a portion of their securities at any time, which could lead to significant share price volatility if a large block of shares is sold.
• The Reporting Persons may propose or participate in future transactions, including extraordinary corporate transactions such as mergers, reorganizations, liquidations, or sales of material assets, which could alter the company's structure or strategic direction.
• The lock-up agreement restricts sales for 180 days, but after this period, a large volume of shares could become available for sale, potentially impacting market price.

Future Outlook

The Reporting Persons intend to hold their securities for investment purposes but reserve the right to purchase additional securities or dispose of all or a portion of their current holdings at any time. They may also propose or participate in future extraordinary corporate transactions, such as mergers, reorganizations, liquidations, or sales of material assets.

Management Comments

• "The Reporting Persons purchased the aforementioned securities for investment purposes with the aim of increasing the value of their investments and the Issuer."
• "Dr. Akkaraju, the Managing Member of Samsara GP, is a member of the board of directors of the Issuer. As a director of the Issuer, Dr. Akkaraju may have influence over the corporate activities of the Issuer..."

Industry Context

This filing reflects a common strategy in the biotechnology and pharmaceutical sectors where venture capital firms invest significantly in emerging companies, often facilitating mergers or acquisitions to consolidate assets or advance pipelines. Samsara BioCapital's substantial stake in Kalaris Therapeutics, Inc. post-merger positions it as a key influencer in the company's strategic direction, typical of venture capital involvement in life sciences.

Corporate Governance

Related Party Transactions

• Dr. Srinivas Akkaraju, as the Managing Member of Samsara BioCapital GP, LLC (a Reporting Person) and a member of the Issuer's Board of Directors, may receive stock options or other equity-based compensation from the Issuer pursuant to its non-employee director compensation arrangements.

Stakeholder Impact

• Shareholders: The significant ownership stake by Samsara BioCapital could provide stability and strategic direction, but also introduces the potential for future large-scale share transactions by a major holder. The lock-up agreement temporarily restricts sales by key insiders.
• Management: Dr. Akkaraju's board membership means direct influence from a major investor on corporate activities and strategic decisions.

Next Steps

• The Reporting Persons may purchase additional securities of the Issuer from time to time.
• The Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time.
• The Reporting Persons reserve the right to propose or participate in future extraordinary corporate transactions (e.g., merger, reorganization, liquidation, asset sale).
• The 180-day lock-up period for certain shares will expire, after which those shares may be sold or transferred.

Key Dates

Keywords

Kalaris Therapeutics, Samsara BioCapital, Schedule 13D, beneficial ownership, merger, biotechnology, venture capital, SEC filing, common stock, investment